Latest Earnings Results: Q2 '26
Estimated EPS
$0.28
Reported EPS
$0.29
Surprise
+4.32%
Estimated Rev
$100.47M
Reported Rev
$101.93M
Surprise
+1.46%
• Reported GAAP EPS of $0.33 up 13.79% YoY • Reported revenue of $101.93M up 156.52% YoY • CorMedix maintains full-year 2026 consolidated revenue guidance of $325 to $345 million, raises full-year adjusted EBITDA guidance to $125 to $140 million, and narrows cash OpEx guidance to $145 to $155 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.10 | -- | -- | N/A |
Q2 '26 | $0.28 | $0.29 | 4.32% | BEAT |
Q1 '26 | $0.34 | $0.43 | 25.42% | BEAT |
Q4 '25 | $0.82 | $0.16 | -80.40% | MISSED |
Q3 '25 | $0.63 | $1.26 | 98.65% | BEAT |